Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers
Objective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020. Methods: CHANNEL was a large,...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2024-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/21/12/1171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539720227225600 |
|---|---|
| author | Zhihao Lu Mingfei Geng Yongtao Han Jianzhong Cao Jun Wang Tianshu Liu Xianglin Yuan Xue Meng Yanqiao Zhang Rong Zhao Lixin Wan Enxiao Li Wenran Wang Zhijie Li Danfeng Shi Jing Qian Si Shi Fengshi Dong Lin Shen |
| author_facet | Zhihao Lu Mingfei Geng Yongtao Han Jianzhong Cao Jun Wang Tianshu Liu Xianglin Yuan Xue Meng Yanqiao Zhang Rong Zhao Lixin Wan Enxiao Li Wenran Wang Zhijie Li Danfeng Shi Jing Qian Si Shi Fengshi Dong Lin Shen |
| author_sort | Zhihao Lu |
| collection | DOAJ |
| description | Objective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020. Methods: CHANNEL was a large, retrospective study using patient-level data from 14 hospitals/cancer centers across China, including adults initiating therapy for newly diagnosed EC (January to December 2018). Demographics, clinicopathologic characteristics, and treatment patterns over 6 months were descriptively summarized. Results: Of 3,493 patients, 75.7% were men, the mean age was 64.1 years, and 75.0% had no family history of cancer. Most (92.8%) had squamous cell carcinoma, with a primary lesion in the middle esophagus (56.4%). Among patients with resectable EC, 92.9% received initial surgery, and 7.1% received neoadjuvant therapy, primarily chemotherapy (85.5% platinum-taxane). Among patients with unresectable early or locally advanced EC, 50.8% and 49.2% received palliative and radical therapy, respectively, as the initial treatment, primarily chemotherapy (66.5% platinum-taxane) and chemoradiotherapy (50.8% platinum-taxane), respectively. Adjuvant therapy was administered to 22.9% of patients undergoing initial surgery, and 2.4% receiving neoadjuvant therapy and surgery. Among patients with advanced EC, 84.6% received systemic therapy as an initial treatment, primarily chemotherapy (61.5% platinum-taxane). Conclusions: Before the approval of immunotherapy in China, most patients with resectable early or locally advanced EC underwent radical surgery without preoperative treatment, whereas most patients with advanced EC received platinum-taxane chemotherapy. These findings highlight the need for novel EC treatments before immunotherapy was introduced, and provide a baseline for evaluating the benefits of immunotherapy, now that this treatment is widely used in this setting. |
| format | Article |
| id | doaj-art-f40cdc8a63f440f9baeb6e5717099c8d |
| institution | Kabale University |
| issn | 2095-3941 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj-art-f40cdc8a63f440f9baeb6e5717099c8d2025-02-05T09:57:38ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412024-12-0121121171118410.20892/j.issn.2095-3941.2024.0336Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centersZhihao Lu0Mingfei Geng1Yongtao Han2Jianzhong Cao3Jun Wang4Tianshu Liu5Xianglin Yuan6Xue Meng7Yanqiao Zhang8Rong Zhao9Lixin Wan10Enxiao Li11Wenran Wang12Zhijie Li13Danfeng Shi14Jing Qian15Si Shi16Fengshi Dong17Lin Shen18Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaDepartment of Thoracic Surgery, Anyang Cancer Hospital, Anyang 455001, ChinaDepartment of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu 610042, ChinaDepartment of Radiotherapy, Shanxi Provincial Cancer Hospital, Taiyuan 030013, ChinaDepartment of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, ChinaDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Radiotherapy, Shandong Cancer Hospital, Jinan 250117, ChinaDepartment of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin 150081, ChinaDepartment of Pharmacy, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, ChinaDepartment of Medical Oncology, Nanyang Central Hospital, Nanyang 473005, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of the Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, ChinaDepartment of Thoracic Surgery, Weifang Second People’s Hospital, Weifang 261041, ChinaValue & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai 200233, ChinaValue & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai 200233, ChinaValue & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai 200233, ChinaValue & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai 200233, ChinaState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaObjective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020. Methods: CHANNEL was a large, retrospective study using patient-level data from 14 hospitals/cancer centers across China, including adults initiating therapy for newly diagnosed EC (January to December 2018). Demographics, clinicopathologic characteristics, and treatment patterns over 6 months were descriptively summarized. Results: Of 3,493 patients, 75.7% were men, the mean age was 64.1 years, and 75.0% had no family history of cancer. Most (92.8%) had squamous cell carcinoma, with a primary lesion in the middle esophagus (56.4%). Among patients with resectable EC, 92.9% received initial surgery, and 7.1% received neoadjuvant therapy, primarily chemotherapy (85.5% platinum-taxane). Among patients with unresectable early or locally advanced EC, 50.8% and 49.2% received palliative and radical therapy, respectively, as the initial treatment, primarily chemotherapy (66.5% platinum-taxane) and chemoradiotherapy (50.8% platinum-taxane), respectively. Adjuvant therapy was administered to 22.9% of patients undergoing initial surgery, and 2.4% receiving neoadjuvant therapy and surgery. Among patients with advanced EC, 84.6% received systemic therapy as an initial treatment, primarily chemotherapy (61.5% platinum-taxane). Conclusions: Before the approval of immunotherapy in China, most patients with resectable early or locally advanced EC underwent radical surgery without preoperative treatment, whereas most patients with advanced EC received platinum-taxane chemotherapy. These findings highlight the need for novel EC treatments before immunotherapy was introduced, and provide a baseline for evaluating the benefits of immunotherapy, now that this treatment is widely used in this setting.https://www.cancerbiomed.org/content/21/12/1171esophageal cancerchinaclinicopathologic characteristicstreatment landscaperetrospective |
| spellingShingle | Zhihao Lu Mingfei Geng Yongtao Han Jianzhong Cao Jun Wang Tianshu Liu Xianglin Yuan Xue Meng Yanqiao Zhang Rong Zhao Lixin Wan Enxiao Li Wenran Wang Zhijie Li Danfeng Shi Jing Qian Si Shi Fengshi Dong Lin Shen Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers Cancer Biology & Medicine esophageal cancer china clinicopathologic characteristics treatment landscape retrospective |
| title | Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| title_full | Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| title_fullStr | Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| title_full_unstemmed | Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| title_short | Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| title_sort | retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers |
| topic | esophageal cancer china clinicopathologic characteristics treatment landscape retrospective |
| url | https://www.cancerbiomed.org/content/21/12/1171 |
| work_keys_str_mv | AT zhihaolu retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT mingfeigeng retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT yongtaohan retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT jianzhongcao retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT junwang retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT tianshuliu retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT xianglinyuan retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT xuemeng retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT yanqiaozhang retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT rongzhao retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT lixinwan retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT enxiaoli retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT wenranwang retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT zhijieli retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT danfengshi retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT jingqian retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT sishi retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT fengshidong retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters AT linshen retrospectiveanalysisofdiseasecharacteristicsandtreatmentpatternsamongpatientswithesophagealcanceracross14surgicallyrepresentedcenters |